• Ajay S Sharma, Patrick W Weerwind, Uli Strauch, Arne van Belle, Jos G Maessen, and Emiel F M Wouters.
• Department of Cardiothoracic Surgery, Maastricht University Medical Center, Maastricht, the Netherlands ajay.sharma@maastrichtuniversity.nl.
• Perfusion. 2016 Mar 1; 31 (2): 149-55.

AbstractA novel and portable extracorporeal CO2-removal device was evaluated to provide additional gas transfer, auxiliary to standard therapy in severe acute hypercapnic respiratory failure. A dual-lumen catheter was inserted percutaneously in five subjects (mean age 55 ± 0.4 years) and, subsequently, connected to the CO2-removal device. The median duration on support was 45 hours (interquartile range 26-156), with a blood flow rate of approximately 500 mL/min. The mean PaCO2 decreased from 95.8 ± 21.9 mmHg to 63.9 ± 19.6 mmHg with the pH improving from 7.11 ± 0.1 to 7.26 ± 0.1 in the initial 4 hours of support. Three subjects were directly weaned from the CO2-removal device and mechanical ventilation, one subject was converted to ECMO and one subject died following withdrawal of support. No systemic bleeding or device complications were observed. Low-flow CO2 removal adjuvant to standard therapy was effective in steadily removing CO2, limiting the progression of acidosis in subjects with severe acute hypercapnic respiratory failure.© The Author(s) 2015.

27 keywords...

hide…